Neuroblastoma is one of the most common and most deadly neoplasms of childhood. The studies we have performed over the past 3.5 years were driven by our demonstration that nerve growth factor (NGF) imparts chemoresistance to SY5Y human neuroblastoma cells. Two cell surface receptors, TrkA and p75, have been identified for NGF. We have demonstrated that the relative abundance of p75 and TrkA on the cell surface determines whether p75-NGF contributes to neuroblastoma cell chemoresistance via independent signal transduction or via enhancement of signal transduction through TrkA. We now propose to study the determinants of TrkA-mediated effects on chemotherapeutic agent-induced apoptosis in neural crest tumor cells. We have recently found that overexpression of trkA in some neural crest tumor cells converts the function of TrkA-NGF from anti-apoptotic to pro-apoptotic, and alters the specific pathway through which TrkA-NGF signals. Over the next five years, we propose to extend and use these studies to design approaches that thwart NGF-mediated chemoresistance in neural crest tumors. We hypothesize that (1) TrkA """"""""dose"""""""" determines TrkA-NGF signaling pathway in a cell line-specific manner; (2) the specific signaling pathway triggered by TrkA phosphorylation predicts the function (i.e., pro- or anti-apoptotic) of TrkA-NGF; (3) the in vitro function of TrkA-NGF predicts its function in tumors established from murine xenografts of the same cell line; and (4) combining information regarding TrkA/p75 ratio and TrkA-NGF function facilitates prediction of the antitumor and anti-chemotherapeutic resistance efficacy of NGF receptor agonists and antagonists in vivo. We will test these hypotheses in a series of six sequential specific aims that use in vitro mechanistic information to develop strategies for in vivo approaches to the chemoresistance of neural crest tumors like neuroblastoma, and then test the efficacy of these strategies in our human tumor xenograft model system.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS038569-10
Application #
7408537
Study Section
Special Emphasis Panel (ZRG1-CNBT (01))
Program Officer
Fountain, Jane W
Project Start
1999-12-24
Project End
2010-02-28
Budget Start
2008-03-01
Budget End
2010-02-28
Support Year
10
Fiscal Year
2008
Total Cost
$311,861
Indirect Cost
Name
University of Rochester
Department
Pediatrics
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Schor, Nina F (2018) A Life at the Interface: The 2017 Hower Award Lecture. Pediatr Neurol 80:3-7
Ratner, Nancy; Brodeur, Garrett M; Dale, Russell C et al. (2016) The ""neuro"" of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder. Ann Neurol 80:13-23
Ganeshan, Veena R; Schor, Nina F (2014) p75 neurotrophin receptor and fenretinide-induced signaling in neuroblastoma. Cancer Chemother Pharmacol 73:271-9
Schor, Nina F (2013) Why our patients (and we) need basic science research. Neurology 80:2070-5
Ganeshan, Veena; Ashton, John; Schor, Nina F (2013) p75NTR: an enhancer of fenretinide toxicity in neuroblastoma. Cancer Chemother Pharmacol 71:777-87
Rogers, Danny A; Schor, Nina F (2013) Kidins220/ARMS is expressed in neuroblastoma tumors and stabilizes neurotrophic signaling in a human neuroblastoma cell line. Pediatr Res 74:517-24
Schor, Nina F (2013) Aiming at neuroblastoma and hitting other worthy targets. J Child Neurol 28:768-73
Ganeshan, Veena R; Schor, Nina F (2011) Pharmacologic management of high-risk neuroblastoma in children. Paediatr Drugs 13:245-55
Ingraham, Christopher A; Wertalik, Larissa; Schor, Nina F (2011) Necdin and neurotrophin receptors: interactors of relevance for neuronal resistance to oxidant stress. Pediatr Res 69:279-84
Rogers, Danny; Schor, Nina F (2010) The child is father to the man: developmental roles for proteins of importance for neurodegenerative disease. Ann Neurol 67:151-8

Showing the most recent 10 out of 34 publications